Hyperqbank

_id

683a165dc782e11e38d1b395

id

10562

title

BALL Score for Relapsed/Refractory CLL

full_title

BALL Score for Relapsed/Refractory CLL

short_title

BALL Score

med_description

Evaluates prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (R/R-CLL) on targeted therapies.

short_description

Relapse/refractory CLL prognosis.

slug

ball-score-relapsed-refractory-cll

description

The β2-microglobulin, Anemia, LDH, Last Therapy (BALL) Score evaluates prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) on targeted therapies.

keywords

B2M, Anemia, LDH, Last Therapy (BALL) Score, BALL Score, chronic lymphocytic leukemia, CLL, relapsed/refractory chronic lymphocytic leukemia, RR CLL, β2-microglobulin, anemia, ldh, beta 2 microglobulin, BALL, ibrutinib, BTK, idelalisib, PI3Kδ, venetoclax, BCL2, CLL targeted therapy, progression free survival

complaint

[ "Abdominal Pain", "Fatigue", "Fever", "Loss of Appetite", "Lymphadenopathy", "Weakness", "Weight Loss/Gain", "Hepatosplenomegaly" ]

formula

The BALL score is calculated by adding the selected points for each variable:

evidence

measurements

[]

information

Interpretation:

BALL Score	Risk	24-Month Overall Survival
0-1	Low	89.7%
2-3	Intermediate	79.5%
4	High	55.8%

refrences

{ "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Original/Primary Reference": [ { "href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620111/", "text": "Soumerai JD, Ni A, Darif M, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. The Lancet Haematology. 2019;6(7):e366-e374." } ], "Other References": [ { "href": "https://pubmed.ncbi.nlm.nih.gov/38378673/", "text": "Bennett R, Seymour JF. Update on the management of relapsed/refractory chronic lymphocytic leukemia. Blood Cancer J. 2024;14(1):33." } ], "Outcomes": [], "Validation": [ { "href": "https://ashpublications.org/blood/article/134/Supplement_1/4308/424511/External-Validation-of-a-Novel-Risk-Model-BALL", "text": "Gentile M, Morabito F, Del Poeta G, et al. External validation of a novel risk model (Ball score) in real-world relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus cll study. Blood. 2019;134(Supplement_1):4308-4308." }, { "href": "https://pubmed.ncbi.nlm.nih.gov/32562875/", "text": "Molica S, Baumann TS, Lentini M, Levato L, Delgado J, Montserrat E. The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy. Leukemia Research. 2020;95:106401." } ], "Validations": [] }

pearls

Derivation and validation studies included the use of the following targeted therapies: ibrutinib, idelalisib, and venetoclax.
This tool does not encompass all potential prognostic variables for R/R-CLL. Results should be interpreted within the broader clinical context of each patient.

usecase

Use to estimate survival outcomes in patients with relapsed/refractory chronic lymphocytic leukemia (R/R-CLL) who require further treatment with targeted therapies.

reasons

Identifies patients at increased risk of death despite treatment, which may inform clinical management decisions. Utilizes prognostic factors that are readily obtainable from the patient’s history and laboratory results.

next_advice

Results may be helpful for treatment and goals of care discussions between clinicians and patients, guiding decisions regarding management steps, including alternative therapeutic strategies and enrollment in clinical trials.
Authors of the derivation study suggest that intermediate- and high-risk individuals may benefit from participation in clinical trials.

next_actions

next_management

diseases

[ "Anemia", "Leukemia/Lymphoma" ]

input_schema

{ "conditionality": null, "default": 0, "label_en": "β2-microglobulin", "mdcalc_info_concept": null, "name": "q1", "option_fhir_rules": null, "optional": false, "options": [ { "label": "<5 mg/dL", "value": 0 }, { "label": "≥5 mg/dL", "value": 1 } ], "show_points": true, "tips_en": "", "type": "radio" }

{ "conditionality": null, "default": 0, "label_en": "Anemia", "md_calc_info_concept": null, "name": "q2", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": true, "tips_en": "Hgb <12 g/dL (<120 g/L) for men; <11 g/dL (<110 g/L) for women", "type": "toggle" }

{ "conditionality": null, "default": 0, "label_en": "LDH", "mdcalc_info_concept": null, "name": "q3", "option_fhir_rules": null, "optional": false, "options": [ { "label": "≤Upper limit of normal", "value": 0 }, { "label": ">Upper limit of normal", "value": 1 } ], "show_points": true, "tips_en": "", "type": "radio" }

{ "conditionality": null, "default": 0, "label_en": "Last therapy", "mdcalc_info_concept": null, "name": "q4", "option_fhir_rules": null, "optional": false, "options": [ { "label": "≥24 months", "value": 0 }, { "label": "<24 months", "value": 1 } ], "show_points": true, "tips_en": "Time from initiation", "type": "radio" }

[ { "conditionality": null, "default": 0, "label_en": "β2-microglobulin", "mdcalc_info_concept": null, "name": "q1", "option_fhir_rules": null, "optional": false, "options": [ { "label": "<5 mg/dL", "value": 0 }, { "label": "≥5 mg/dL", "value": 1 } ], "show_points": true, "tips_en": "", "type": "radio" }, { "conditionality": null, "default": 0, "label_en": "Anemia", "md_calc_info_concept": null, "name": "q2", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": true, "tips_en": "Hgb <12 g/dL (<120 g/L) for men; <11 g/dL (<110 g/L) for women", "type": "toggle" }, { "conditionality": null, "default": 0, "label_en": "LDH", "mdcalc_info_concept": null, "name": "q3", "option_fhir_rules": null, "optional": false, "options": [ { "label": "≤Upper limit of normal", "value": 0 }, { "label": ">Upper limit of normal", "value": 1 } ], "show_points": true, "tips_en": "", "type": "radio" }, { "conditionality": null, "default": 0, "label_en": "Last therapy", "mdcalc_info_concept": null, "name": "q4", "option_fhir_rules": null, "optional": false, "options": [ { "label": "≥24 months", "value": 0 }, { "label": "<24 months", "value": 1 } ], "show_points": true, "tips_en": "Time from initiation", "type": "radio" } ]

instructions

published

2024-08-16T17:35:40.742Z

purpose

[ "Prognosis" ]

search_terms

[ "B2M, Anemia, LDH, Last Therapy (BALL) Score", "chronic lymphocytic leukemia", "CLL", "β2-microglobulin", "anemia", "ldh", "beta 2 microglobulin", "BALL", " ibrutinib", "BTK", "idelalisib", "PI3Kδ", "venetoclax", "BCL2", "CLL targeted therapy", "progression free survival" ]

seo

{ "keywords_en": "B2M, Anemia, LDH, Last Therapy (BALL) Score, BALL Score, chronic lymphocytic leukemia, CLL, relapsed/refractory chronic lymphocytic leukemia, RR CLL, β2-microglobulin, anemia, ldh, beta 2 microglobulin, BALL, ibrutinib, BTK, idelalisib, PI3Kδ, venetoclax, BCL2, CLL targeted therapy, progression free survival ", "meta_description_en": "The β2-microglobulin, Anemia, LDH, Last Therapy (BALL) Score evaluates prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) on targeted therapies." }

specialty

[ "Family Practice", "Hematology and Oncology", "Hospitalist Medicine", "Internal Medicine" ]

departments

[ "Hematologic", "Oncologic" ]

version_number

versions

[]

[ { "calcId": 10565, "short_title_en": "IPS-E", "slug": "international-prognostic-score-asymptomatic-early-stage-cll-ips-e" }, { "calcId": 10054, "short_title_en": "Rai Staging for CLL", "slug": "rai-staging-system-chronic-lymphocytic-leukemia-cll" }, { "calcId": 10053, "short_title_en": "Binet Staging for CLL", "slug": "binet-staging-system-chronic-lymphocytic-leukemia-cll" } ]

ismed

false

section

[ "whenToUseViewed", "pearlsPitfallsViewed", "whyUseViewed", "nextStepsViewed", "evidenceViewed" ]

cleaned_departments

[ "hematology", "oncology" ]

cleaned_use

[ "Use to estimate survival outcomes in patients with relapsed/refractory chronic lymphocytic leukemia (R/R-CLL) who require further treatment with targeted therapies." ]

pub